Global Market Study on RNA-based Therapeutics and Vaccines: Post Covid-era to bolster extensive research pertaining to RNA-based therapeutics and vaccines
RNA-Based Therapeutics and Vaccines Market Analysis 2022-2028
A recent market study published by Persistence Market Research (PMR) on the RNA-Based Therapeutics and Vaccines Market including global industry analysis for 2013-2021 & opportunity assessment for 2022-2028, delivers a comprehensive assessment of the most important market dynamics. After conducting a thorough research on the historical as well as current growth parameters of the market, growth prospects are obtained with utmost precision.
RNA-Based Therapeutics and Vaccines Market: Segmentation
The global RNA-Based Therapeutics and Vaccines Market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
Product Type
Workstations
Reagents and Consumables
Kits (RNA sample preparation and DNA sample preparation)
Application
Research Applications
Diagnostic Testing
Clinical Testing
End User
Diagnostic Centers
Hospitals
Academic & Research Institutes
Forensic Science Laboratories
CROs (Contract Research Organizations)
Region
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa (MEA)
Key Questions Answered in Report
The research study offers inclusive insights about the growth of the market in the most comprehensive manner. Key insights offered in the report answer some of the most salient questions that assist stakeholders in gauging all the emerging possibilities.
What are the key trends that are continuously shaping market growth?
Which are the prominent regions that offer plentiful opportunities for players in the market?
How has the outbreak of COVID-19 affected the market and what would the trend be like during the forecast period?
What are the differential strategies adopted by key players to hold a significant share in the RNA-Based Therapeutics and Vaccines industry?
Research Methodology
A unique and promising research methodology forms the base of the market report for the forecast period. This report has been prepared after comprehensive analysis of market events, and riveting insights have been compiled meticulously.
The research methodology is a two-step process comprising primary and secondary research. Key stakeholders, including suppliers, service providers, and experts of several designations, including executive vice presidents, directors, technical advisors, GM marketing professionals, and sales professionals have been interviewed. Secondary sources referred to obtain information include investor presentations of manufacturers, World Bank, IMF, and other credible sources.
The research report includes a competitive landscape that provides a dashboard view of the key competitors operating in the market. Some of the market players included in this section are Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corp., Arrowhead Pharmaceuticals, Inc., BioNTech AG, CureVac AG, Dicerna Pharmaceuticals, Inc., and Regulus Therapeutics, Inc., among others.
- 1. Executive Summary
- 1.1. Market Overview
- 1.2. Market Analysis
- 1.3. PMR Analysis and Recommendations
- 2. Market Introduction
- 2.1. Market Definition
- 2.2. Market Taxonomy
- 3. RNA-based Therapeutics and Vaccines Market Opportunity Analysis
- 3.1. Macro-Economic Factors
- 3.2. Opportunity Analysis
- 4. Market Background
- 4.1. Regulatory Scenario
- 4.2. Market Dynamics
- 4.2.1. Drivers
- 4.2.2. Restraints
- 4.2.3. Opportunity Analysis
- 4.3. Pipeline Assessment
- 5. Gross Domestic Product by Region & Country, 2006 – 2021
- 6. North America RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2022-2028
- 6.1. Introduction
- 6.2. Market Size (US$ Mn) Opportunity Assessment By Country, 2022-2028
- 6.2.1. U.S.
- 6.2.2. Canada
- 6.3. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2022-2028
- 6.3.1. RNA-based Therapeutics
- 6.3.1.1. siRNA
- 6.3.1.2. miRNA
- 6.3.2. RNA-based Vaccines
- 6.3.2.1. mRNA
- 6.4. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2022-2028
- 6.4.1. Oncology
- 6.4.2. Immunology
- 6.4.3. Ophthalmology
- 6.4.4. Cardiovascular Diseases
- 6.4.5. Infectious Diseases
- 6.4.6. Genetic Diseases
- 6.4.7. Others
- 6.5. Drivers and Restraints – Impact Analysis
- 7. Latin America RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2022-2028
- 7.1. Introduction
- 7.2. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2022-2028
- 7.2.1. RNA-based Therapeutics
- 7.2.1.1. siRNA
- 7.2.1.2. miRNA
- 7.2.2. RNA-based Vaccines
- 7.2.2.1. mRNA
- 7.3. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2022-2028
- 7.3.1. Oncology
- 7.3.2. Immunology
- 7.3.3. Ophthalmology
- 7.3.4. Cardiovascular Diseases
- 7.3.5. Infectious Diseases
- 7.3.6. Genetic Diseases
- 7.3.7. Others
- 7.4. Drivers and Restraints – Impact Analysis
- 8. Europe RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2022-2028
- 8.1. Introduction
- 8.2. Market Size (US$ Mn) Opportunity Assessment By Country, 2022-2028
- 8.2.1. Germany
- 8.2.2. U.K.
- 8.2.3. France
- 8.2.4. Italy
- 8.2.5. Spain
- 8.2.6. Russia
- 8.2.7. Rest of Europe
- 8.3. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2022-2028
- 8.3.1. RNA-based Therapeutics
- 8.3.1.1. siRNA
- 8.3.1.2. miRNA
- 8.3.2. RNA-based Vaccines
- 8.3.2.1. mRNA
- 8.4. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2022-2028
- 8.4.1. Oncology
- 8.4.2. Immunology
- 8.4.3. Ophthalmology
- 8.4.4. Cardiovascular Diseases
- 8.4.5. Infectious Diseases
- 8.4.6. Genetic Diseases
- 8.4.7. Others
- 8.5. Drivers and Restraints – Impact Analysis
- 9. Asia Pacific RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2022-2028
- 9.1. Introduction
- 9.2. Market Size (US$ Mn) Opportunity Assessment By Country, 2022-2028
- 9.2.1. China
- 9.2.2. Japan
- 9.2.3. Australia & New Zealand
- 9.2.4. Rest of APAC
- 9.3. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2022-2028
- 9.3.1. RNA-based Therapeutics
- 9.3.1.1. siRNA
- 9.3.1.2. miRNA
- 9.3.2. RNA-based Vaccines
- 9.3.2.1. mRNA
- 9.4. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2022-2028
- 9.4.1. Oncology
- 9.4.2. Immunology
- 9.4.3. Ophthalmology
- 9.4.4. Cardiovascular Diseases
- 9.4.5. Infectious Diseases
- 9.4.6. Genetic Diseases
- 9.4.7. Others
- 9.5. Drivers and Restraints – Impact Analysis
- 10. Middle East & Africa RNA-based Therapeutics and Vaccines Opportunity Assessment 2022-2028
- 10.1. Introduction
- 10.2. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2022-2028
- 10.2.1. RNA-based Therapeutics
- 10.2.1.1. siRNA
- 10.2.1.2. miRNA
- 10.2.2. RNA-based Vaccines
- 10.2.2.1. mRNA
- 10.3. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2022-2028
- 10.3.1. Oncology
- 10.3.2. Immunology
- 10.3.3. Ophthalmology
- 10.3.4. Cardiovascular Diseases
- 10.3.5. Infectious Diseases
- 10.3.6. Genetic Diseases
- 10.3.7. Others
- 10.4. Drivers and Restraints – Impact Analysis
- 11. Competition Analysis
- 11.1. Competition Dashboard
- 12. Company Profiles
- 12.1. Company Deep Dive
- 12.1.1. Alnylam Pharmaceuticals, Inc.
- 12.1.2. Arbutus Biopharma Corp.
- 12.1.3. Arrowhead Pharmaceuticals, Inc.
- 12.1.4. BioNTech AG
- 12.1.5. CureVac AG
- 12.1.6. Dicerna Pharmaceuticals, Inc.
- 12.1.7. Regulus Therapeutics, Inc.
- 12.1.8. Marina Biotech, Inc.
- 12.1.9. miRagen Therapeutics
- 12.1.10. Moderna Therapeutics, Inc.
- 12.1.11. Quark Pharmaceuticals, Inc.
- 12.1.12. Santaris Pharma A/S (A Roche Company)
- 12.1.13. Sylentis S.A.
- 13. Global RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2022-2028, By Region
- 13.1. Introduction/Key Findings
- 13.2. Market Size (US$ Mn) Opportunity Assessment By Region, 2022-2028
- 13.2.1. North America
- 13.2.2. Latin America
- 13.2.3. Europe
- 13.2.4. Asia Pacific Excluding China
- 13.2.5. Middle East & Africa
- 13.2.6. China
- 13.3. Market Attractiveness Analysis By Region
- 14. Global Product Opportunity Assessment 2022-2028, By Product Type
- 14.1. Introduction/Key Findings
- 14.2. Market Size (US$ Mn) and Volume Opportunity Assessment By Product Type, 2022-2028
- 14.2.1. RNA-based Therapeutics
- 14.2.1.1. siRNA
- 14.2.1.2. miRNA
- 14.2.2. RNA-based Vaccines
- 14.2.2.1. mRNA
- 14.3. Market Attractiveness Analysis By Product Type
- 15. Global Product Opportunity Assessment 2022-2028, By Indication Type
- 15.1. Introduction/Key Findings
- 15.2. Market Size (US$ Mn) and Volume Opportunity Assessment By Indication Type, 2022-2028
- 15.2.1. Oncology
- 15.2.2. Immunology
- 15.2.3. Ophthalmology
- 15.2.4. Cardiovascular Diseases
- 15.2.5. Infectious Diseases
- 15.2.6. Genetic Diseases
- 15.2.7. Others
- 15.3. Market Attractiveness Analysis By Indication
- 16. Global Product Opportunity Assessment 2022-2028
- 16.1. Market Opportunity Assessment By All Segment
- 16.2. Absolute $ Opportunity
- 17. Assumption & Acronyms Used
- 18. Research Methodology
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook